IPGaia (IPG) promotes R&D with the aim of acquiring precious intellectual property for the commercialization of new pharmaceuticals, such as composition of matter patents. IPG will select and develop promising research programs and license them out to pharmaceutical companies.
IPG aims to create an ecosystem to assist in the development of new drugs, especially for personalized medicine.
Our mission is to support pharmaceutical companies in the development of a small quantity of a wide variety of drugs to meet the individual medical needs and deliver them quickly, safely, and effectively to as many patients as possible.
| Name of the Company | IPGaia, Inc. | |
|---|---|---|
| Location | 2-5-1 Atago, Minato-ku, Tokyo 105-6236 | |
| Investor | Healthcare New Platform Fund（100％） General Partner; Whiz Partners Inc. | |
| Capital and Capital Reserves | 10 million JPY | |
| Established | October 26th, 2021 | |
| Business Scope |
| |
| Management | President & CEO Chairman | Yasunori Yamaguchi Satoru Iino |
IPGaia, Inc (IPG) has entered an agreement to collaborate with researchers at Weill Cornell Medicine-Qatar (WCM-Q) to investigate promising targets for the development of new medicines. The Master Collaborative Research and Development Agreement was signed in October 2023 by IPG and Cornell University, based in Ithaca, New York, USA. WCM-Q, based in Doha, is a location of Weill Cornell Medicine in New York, which is part of Cornell University. The Master Agreement establishes a formal framework for the incorporation of promising drug target leads discovered at WCM-Q into IPG’s drug discovery platform. The agreement enables WCM-Q to propose drug targets to IPG for identification and development of lead compounds …
IPGaia Inc. (President & CEO, Yasunori Yamaguchi, “IPG”) and Kyoto University (Provost, Nagahiro Minato) have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated November 17, 2023. This agreement establishes a formal framework for the incorporation of promising drug target leads from Kyoto University into IPG’s drug discovery platform. This agreement enables Kyoto University to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. IPG is soliciting drug target leads from a wide range of research institutions, including global academia and pharmaceutical companies, and is steadily expanding to the seventh institution, Kyoto …
SINGAPORE, 7 November 2023 – Duke-NUS Medical School (Duke-NUS) and IPGaia, Inc. (IPG) have signed an agreement to jointly advance drug discovery and development from academia to industry, to bring the benefits of translational research to patients. Through this partnership, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies. The collaboration brings together IPG’s expertise in commercial research and development and its industry network with Duke-NUS’ strong capabilities in world-class discovery research in areas of global importance. Aligning with Singapore’s national focus to build a vibrant ecosystem for biomedical innovation, Duke-NUS’ five …
